BMC Cancer: Nab-paclitaxel combined with PD-1 inhibitor sintilimab is a promising treatment for advanced soft tissue sarcoma (STS)

Albumin paclitaxel combined with PD-1 inhibitors showed good antitumor activity in a variety of tumors
.

However, its efficacy in advanced soft tissue sarcoma (STS) remains unclear

Albumin paclitaxel combined with PD-1 inhibitors showed good antitumor activity in a variety of tumors

The study included 28 patients with advanced soft tissue sarcoma (STS) treated with nab-paclitaxel combined with the PD-1 inhibitor sintilimab, including 15 women and 13 men
.

Histological subtypes included undifferentiated pleomorphic sarcoma (7 cases), angiosarcoma (5 cases), epithelioid sarcoma (5 cases), fibrosarcoma (4 cases), synovial sarcoma (3 cases), leiomyosarcoma (2 cases) case), pleomorphic liposarcoma (1 case) and rhabdomyosarcoma (1 case)

The study included 28 patients with advanced soft tissue sarcoma (STS) treated with nab-paclitaxel combined with the PD-1 inhibitor sintilimab, including 15 women and 13 men

Among 28 patients with advanced STS, 1 patient with angiosarcoma was CR, 6 patients were PR, and 7 patients were SD

Efficacy and prognosis

Efficacy and prognosis

The most common grade 1 or 2 AEs were alopecia (89.
3%; 25/28), leukopenia (25.
0%; 7/28), fatigue (21.
4%; 6/28), anemia (21.
4%; 6/28) ), nausea (21.
4%; 6/28)
.

The most common grade 3 AEs were neutropenia (10.

The most common grade 1 or 2 AEs were alopecia (89.

AEs

AEs

In our patient cohort, patients with angiosarcoma had significantly longer PFS than other pathological subtypes (HR = 0.
20, 95% CI 0.
06 - 0.
70, P = 0.
012); patients with primary sites in the head had significantly longer PFS than patients with other sites (HR = 0.
20, 95%CI 0.
04 to 0.
99, P = 0.
048); patients with three or more AEs had significantly longer PFS than those with less than three (HR = 0.
36, 95%CI 0.
16 - 0.
84, P = 0.
018)
.

In our patient cohort, patients with angiosarcoma had significantly longer PFS than other pathological subtypes (HR = 0.
20, 95% CI 0.
06 - 0.
70, P = 0.
012); patients with primary sites in the head had significantly longer PFS than patients with other sites (HR = 0.
20, 95%CI 0.
04 to 0.
99, P = 0.
048); patients with three or more AEs had significantly longer PFS than those with less than three (HR = 0.
36, 95%CI 0.
16 - 0.
84, P = 0.
018)
.

In our patient cohort, patients with angiosarcoma had significantly longer PFS than other pathological subtypes (HR = 0.

             Subgroup analysis

Subgroup analysis

In conclusion, studies have shown that nab-paclitaxel combined with PD-1 inhibitor sintilimab can be an effective treatment for advanced soft tissue sarcoma (STS)
.

In conclusion, studies have shown that nab-paclitaxel combined with PD-1 inhibitor sintilimab can be an effective treatment for advanced soft tissue sarcoma (STS)
.

Studies have shown that nab-paclitaxel combined with the PD-1 inhibitor sintilimab can be an effective treatment option for advanced soft tissue sarcoma (STS)

Original source:

Tian Z, Dong S, Yang Y, Gao S, Yang Y, Yang J, Zhang P, Wang X, Yao W.

Tian Z, Dong S, Yang Y, Gao S, Yang Y, Yang J, Zhang P, Wang X, Yao W.
Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study .
BMC Cancer.
2022 Jan 12;22(1):56.
doi: 10.
1186/s12885-022-09176-1.
PMID: 35022029.
Leave a comment here